Preimplantation Genetic Screening (PGS) in Advanced Female Age and Male Severe Factor
Embryo Aneuploidies, Implantation Rates, Infertility
About this trial
This is an interventional prevention trial for Embryo Aneuploidies focused on measuring PGS, CGH, Aneuploidy, Advanced maternal age, Male factor
Eligibility Criteria
Inclusion Criteria: ADVANCED AGE and SEVERE MALE FACTOR:
- Women's Age: 38- 41 years old (both included)
- Men's Age: 18-60 years old (both included)
- Ovulation triggered with human chorionic gonadotrophin (hCG) (Ovitrelle, Merck-Serono, Madrid)
- Number of Oocytes metaphase II (MII): ≥ 5 (fresh, not vitrified)
- Quality of semen: ≥ 5 millions spermatozoids/ml
Exclusion Criteria: ADVANCED AGE and SEVERE MALE FACTOR:
- Number of Oocytes metaphase II (MII): <5 oocytes
- Number of Oocytes obtained: >20
- Estradiol on the day of human chorionic gonadotrophin (hCG) >3000 pgr/ml administration.
- Progesterone on the day of hCG >1,5 pmol/l administration
- ≥ 2 previous miscarriages:biochemical,clinical,ectopic or a combination)
- Any un corrected alteration in a previous study.
- Other indications of (Preimplantation Genetic Diagnosis.Screening) PGD-S, such as monogenic illnesses, translocations, repeated implantation failure, repeated miscarriages, etc.
Sites / Locations
- SPAIN: IVI Valencia, IVI Barcelona, IVI Madrid
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Experimental
Experimental
Active Comparator
Active Comparator
Group B - Severe Male Factor
Group B - Advanced Age
Group A - Advanced Age
Group A - Severe Male Factor
PGS of day three biopsies and consequent embryo transfer on on Day 5 (blastocyst)
PGS of day three biopsies and consequent embryo transfer on on Day 5 (blastocyst)
Prolonged culture, no PGS, for Day 5 (blastocyst) embryo transfer for the Advanced Age group
Prolonged culture, no PGS, for Day 5 (blastocyst) embryo transfer for the Severe Male Factor group.